Nasdaq: VRTX
News & Events
Press Release Details
Vertex Awards 40 Scholarships Totaling $200,000 to People Living with Cystic Fibrosis and Their Immediate Family Members
- New Program Helps CF Families Pursue Higher Education -
Vertex established the All in for CF Scholarship program to help people with cystic fibrosis (CF) and their immediate family members pursue two-year, four-year or graduate degrees. These scholarships complement other Vertex initiatives that help people with CF live active lives, improve awareness of CF, and support independent basic science and clinical research.
"Vertex is focused on discovering and developing transformative
medicines for people with CF, but our commitment to the community
extends far beyond this," said
Scholarship recipients were chosen by an independent committee of CF community members based on a submitted essay and an applicant's demonstrated level of community involvement, financial need, and academic achievement. Vertex thanks the members of the CF community who volunteered to serve on the selection committee, for their time and commitment.
"I believe I was given a second chance to inspire, love and help
others," said
More information about the All in for CF Scholarship, including biographies for some of this year's recipients, can be found here.
About Cystic Fibrosis
Cystic fibrosis is a rare,
life-threatening genetic disease affecting approximately 75,000 people
in North America, Europe and Australia. CF is caused by a defective or
missing CFTR protein resulting from mutations in the CFTR gene.
Children must inherit two defective CFTR genes — one
from each parent — to have CF. There are approximately 2,000 known
mutations in the CFTR gene. Some of these mutations,
which can be determined by a genetic test, lead to CF by creating
defective or too few CFTR proteins at the cell surface. The defective or
missing CFTR protein results in poor flow of salt and water into or out
of the cell in a number of organs, including the lungs. This leads to
the buildup of abnormally thick, sticky mucus that can cause chronic
lung infections and progressive lung damage in many patients that
eventually leads to death. The median predicted age of survival for a
person born today with CF is 41 years, but the median age of death is 27
years.
About Vertex
Vertex is a global biotechnology company that
aims to discover, develop and commercialize innovative medicines so
people with serious diseases can lead better lives. In addition to our
clinical development programs focused on cystic fibrosis, Vertex has
more than a dozen ongoing research programs aimed at other serious and
life-threatening diseases.
Founded in 1989 in
Vertex Is All In for CF
The CF community motivates Vertex
employees each and every day - to dig deeper, to do more, to explore the
"what ifs," and to push the boundaries of what we know. We aim to
discover and develop medicines that will treat the underlying cause of
CF for the vast majority of people with the disease, and our ultimate
goal is to cure it. Beyond our transformational medicines, we help
people with CF lead active lives and pursue higher education, and we
fund independent research and innovative patient centric programs. To
learn more please visit www.vrtxallincf.com.
(VRTX-GEN)
View source version on businesswire.com: http://www.businesswire.com/news/home/20170519005078/en/
mediainfo@vrtx.com
Source:
News Provided by Acquire Media